Clinical trial
BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors
NCT00043095 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00043095 |
|---|---|
| Title | BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Trial of BMS 247550 (NSC# 710428) and Gemcitabine in Patients With Advanced Solid Tumor Malignancies |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, ixabepilone |
| Start date | Jun 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: